Skip to main content

Quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells (EMEA)

 Guideline on quality, non-clinical, and clinical aspects of medicinal products containing genetically modified cells" is a regulatory or guidance document issued by a health authority or regulatory agency. This guideline provides comprehensive guidance and requirements for the development, evaluation, and approval of medicinal products that contain genetically modified cells. Here's an overview of the key aspects typically covered in such a guideline:


1. Introduction:

The document likely begins with an introduction, explaining the purpose and scope of the guideline. It may also provide background information on the use of genetically modified cells in medicinal products.

2. Quality Aspects:

Quality considerations are a critical part of any medicinal product development. The guideline may provide detailed requirements for the quality control and assurance of genetically modified cells, including:

  • Characterization of the genetically modified cells.
  • Manufacturing processes, including cell culture, genetic modification, and downstream processing.
  • Testing methods for assessing the identity, potency, purity, and safety of the cells.
  • Control of raw materials and reagents used in cell production.
  • Stability testing to determine the shelf life and storage conditions of the product.

3. Non-Clinical Aspects:

  • The non-clinical section of the guideline would focus on preclinical studies and data requirements. This may include:
  • In vitro and in vivo studies to evaluate the safety, efficacy, and biodistribution of the genetically modified cells.
  • Assessment of potential toxicities and immune responses.
  • Consideration of off-target effects of genetic modifications.
  • Data on the persistence and fate of the modified cells in animal models.

4. Clinical Aspects:

This section addresses clinical trials involving genetically modified cells, including:

  • Requirements for designing and conducting clinical trials, including Phase I, II, and III studies.
  • Informed consent and ethical considerations.
  • Patient eligibility criteria and patient monitoring during trials.
  • Data collection and analysis for safety and efficacy.
  • Reporting of adverse events and serious adverse events.
  • Long-term follow-up of patients to assess the durability of therapeutic effects and potential long-term risks.

5. Regulatory Considerations:

The document may outline the regulatory pathways and requirements for the approval of medicinal products containing genetically modified cells. This includes interactions with regulatory agencies, submission of regulatory documents, and compliance with regulatory standards.

6. Risk Management and Pharmacovigilance:

Guidelines often include recommendations for risk management plans and pharmacovigilance activities to monitor the safety of these products after they are on the market.

7. Post-Market Surveillance:

There may be recommendations for post-market surveillance and data collection to assess the long-term safety and efficacy of these products in real-world settings.

8. References and Appendices:

The document includes references to relevant scientific literature and may include appendices with additional details or forms for regulatory submissions.

https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-non-clinical-clinical-aspects-medicinal-products-containing-genetically-modified_en-0.pdf


Popular posts from this blog

SOP on Investigator Delegation of Authority

Title: Investigator Delegation of Authority Introduction and Purpose: This Standard Operating Procedure (SOP) outlines the process by which the Principal Investigator (PI) delegates the authority to conduct clinical study procedures and tasks to sub-investigators and other study personnel. It also details the maintenance of documentation related to staff and investigator signatures and handwriting samples. Scope: The PI conducting a clinical trial must adhere to regulations governing informed consent (21 CFR 50) and regulations regarding Institutional Review Board (IRB) review and approval (21 CFR 56). If the study involves an investigational drug or device, additional regulations in 21 CFR 312 or 21 CFR 812 apply. Furthermore, all clinical study investigators should follow the International Council on Harmonization (ICH) guidelines for Good Clinical Practice (GCP). While these responsibilities are primarily held by the PI, they can be delegated to qualified sub-investigators and other...
Read more

ICH Topic Q5E Comparability of biotechnological/biological products (CPMP/ICH/5721/03)

 ICH Topic Q5E, as outlined in document CPMP/ICH/5721/03, deals with the comparability of biotechnological and biological products. This guideline provides a structured framework for assessing and ensuring the comparability of different product versions, including changes during development, manufacturing, or post-approval phases. The goal is to demonstrate that changes made to a product do not adversely affect its quality, safety, or efficacy. Here's an elaboration of ICH Q5E: 1. Purpose of ICH Q5E: The primary purpose of ICH Q5E is to provide guidance on how to demonstrate the comparability of biotechnological and biological products, especially when changes are made to the manufacturing process or product characteristics. Comparability studies are crucial for ensuring the consistent quality and safety of these products. 2. Types of Changes Covered: ICH Q5E covers a wide range of changes, including modifications to the manufacturing process, changes in the manufacturing site, alt...
Read more

Ago2 Immunoprecipitation for RISC-siRNA Quantitation

 Ago2 (Argonaute 2) immunoprecipitation (IP) is a technique used to isolate RNA-induced silencing complexes (RISC) from cell lysates. This method allows for the specific enrichment of active RISC complexes bound to small interfering RNA (siRNA) or microRNA (miRNA) within cells. By isolating these complexes, researchers can then quantify the siRNA associated with Ago2, which is an essential step in determining the efficacy of RISC loading and siRNA activity. Here’s a detailed overview of how Ago2 immunoprecipitation is performed for RISC-siRNA quantitation: Steps in Ago2 Immunoprecipitation for RISC-siRNA Quantitation Cell Lysis and Preparation of Lysate : Sample Preparation : Collect cells that have been treated with siRNA, then wash them with cold phosphate-buffered saline (PBS) to remove extracellular contaminants. Lysis : Lyse the cells in a gentle, RNA-preserving lysis buffer that typically includes detergents (e.g., NP-40 or Triton X-100), protease inhibitors, and RNase inhibi...
Read more

ICH Q5D Derivation and characterisation of cell substrates used for production of biotechnological/biological products (CPMP/ICH/294/95)

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides guidelines to ensure the quality, safety, and efficacy of pharmaceutical products. ICH Q5D, as outlined in document CPMP/ICH/294/95, addresses the derivation and characterization of cell substrates used for the production of biotechnological and biological products. Below is a detailed elaboration of ICH Q5D: 1. Purpose of ICH Q5D: ICH Q5D provides guidelines for the establishment of cell substrates used in the production of biotechnological and biological products. The primary goal is to ensure the quality, safety, and consistency of cell substrates to minimize potential risks associated with the final product. 2. Cell Substrate Characterization: The guideline emphasizes the importance of thorough characterization of the cell substrate. This includes the origin of the cells, their history, and any relevant genetic information. Detailed documentation of the cell line...
Read more

Safety Concerns for AAV Gene Therapy

 Adeno-associated virus (AAV) gene therapies have shown significant therapeutic promise, but they also carry risks, and toxicity signals are a primary safety concern. While generally well-tolerated, AAV-based therapies can trigger adverse effects ranging from immune-related responses to cellular toxicities, especially at higher doses. Here’s an overview of the key toxicity signals associated with AAV gene therapy, along with potential mechanisms and mitigation strategies: 1. Liver Toxicity Signal : Hepatotoxicity is one of the most common toxicity signals with AAV gene therapy, especially with high vector doses or in patients with pre-existing liver disease. Mechanism : AAV vectors, often targeting the liver, can cause liver inflammation due to: Immune responses to AAV capsids. Overexpression of the therapeutic transgene, leading to cellular stress. Clinical Signs : Elevated liver enzymes (ALT, AST) are common indicators of hepatotoxicity. Mitigation : Strategies include using immu...
Read more